Compare Medpace Holdings Inc (MEDP) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs MakeMyTrip Ltd — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while MakeMyTrip Ltd trades at $44.73 (market cap $4.09B). The key difference: Medpace Holdings Inc is far larger — about 4.1× MakeMyTrip Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and MakeMyTrip Ltd for 12 Days on average.
| MEDP | MMYT | |
|---|---|---|
Market Cap | $16.82B | $4.09B |
Volume | 223,093 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $94.43 |
52-Week Low | $393.42 | $36.30 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | $16.44B | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
